公开(公告)号：EP2331136A4

公开(公告)日：2013-01-23

申请号：EP09817004

申请日：2009-09-28

申请人： ONCOMED PHARM INC

发明人： GURNEY AUSTIN L ,  SATO AARON KEN ,  AXELROD FUMIKO TAKADA ,  HOEY TIMOTHY CHARLES ,  SATYAL SANJEEV H ,  MITRA SATYAJIT SUJIT KUMAR

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/28 ,  A61K31/00 ,  A61K31/337 ,  A61K31/7068 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  G01N33/5011 ,  A61K2300/00

摘要： Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.

摘要翻译： 提供了新的抗癌剂，包括但不限于与人类卷曲蛋白受体结合的抗体。 还鉴定了适合作为抗癌剂靶标的人类卷曲蛋白受体内的新表位。 还提供了使用所述试剂或抗体的方法，例如使用所述试剂或抗体抑制Wnt信号传导和/或抑制肿瘤生长的方法。

公开(公告)号：EP2307051A4

公开(公告)日：2012-07-18

申请号：EP09794821

申请日：2009-07-08

申请人： ONCOMED PHARM INC

发明人： GURNEY AUSTIN L ,  HOEY TIMOTHY CHARLES ,  HTUN VAN DER HORST EDWARD THEIN ,  SATO AARON KEN ,  LIU YUAN CHING ,  BRUHNS MAUREEN FITCH ,  LEWICKI JOHN A

IPC分类号： C07K16/28 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K31/337 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/10 ,  C07H21/04 ,  C07K14/435 ,  C07K14/71 ,  C07K16/22 ,  C07K16/30 ,  C07K16/3046 ,  C07K16/462 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12N5/0693 ,  C12N5/12 ,  C12N15/63 ,  C12N15/79 ,  C12N2501/998

摘要： The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明提供了用于癌症的诊断，表征，预后和治疗以及特异性靶向癌症干细胞的方法和方法。 本发明提供了与人Notch受体的细胞外结构域的非配体结合膜近端区域特异性结合并抑制肿瘤生长的抗体。 本发明还提供了一种治疗癌症的方法，所述方法包括施用治疗有效量的特异性结合人Notch受体蛋白的细胞外结构域的非配体结合膜近端区域并抑制肿瘤生长的抗体。

公开(公告)号：EP2424567A4

公开(公告)日：2013-07-17

申请号：EP10772544

申请日：2010-04-27

申请人： ONCOMED PHARM INC

发明人： GURNEY AUSTIN L ,  SATO AARON KEN

IPC分类号： C12P21/08

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  A61K51/1021 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/468 ,  C07K2317/20 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/00

摘要： Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.

公开(公告)号：EP2331136B1

公开(公告)日：2018-01-10

申请号：EP09817004

申请日：2009-09-28

申请人： ONCOMED PHARM INC

发明人： GURNEY AUSTIN L ,  SATO AARON KEN ,  AXELROD FUMIKO TAKADA ,  HOEY TIMOTHY CHARLES ,  SATYAL SANJEEV H ,  MITRA SATYAJIT SUJIT KUMAR

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/28 ,  A61K31/00 ,  A61K31/337 ,  A61K31/7068 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  G01N33/5011 ,  A61K2300/00

摘要： Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.

公开(公告)号：EP2758073A4

公开(公告)日：2015-04-29

申请号：EP12833767

申请日：2012-09-24

申请人： ONCOMED PHARM INC

发明人： GURNEY AUSTIN L ,  SATO AARON KEN ,  BOND CHRISTOPHER JOHN

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K16/00 ,  C12P21/08

CPC分类号： C07K16/28 ,  A61K31/4745 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/00 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/22 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3046 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.